-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target

Benzinga·07/07/2026 11:50:34
Listen to the news
Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.